Advocate Audience Demographics

A total of 32 advocates attended the Symposium and responded to a few questions about their background, constituencies, and precision medicine. Most (83%) were cancer survivors and were split as to whether their primary reaction to precision medicine was excitement (41%) or being full of questions (59%). Advocates represented SWOG (31%), ECOG-ACRIN (28%), NCI Steering Committee (17%), the Alliance (14%), and the NRG (10%). Advocates’ primary patient constituencies were breast cancer (26%), colorectal cancer (17%), ovarian cancer (13%), and prostate cancer (9%), with the remaining cancers represented by a single advocate.
**Advocate Audience Questions on Precision Medicine**

Most advocates (61%) indicated that the patients they serve do not ask about tumor profiling. Advocates believed that most patients get information about tumor profiling from the healthcare team (38%), other medical sites (28%), support groups and chat rooms (24%), and advocate organization websites (10%). Additional results are shown in the following graphs.
Think Tank

A Think Tank was convened on the final day of the Symposium to explore ideas from advocates for future precision medicine trials. Advocates were broken out into small groups to address 3 major issues in precision medicine trials: Communications, Logistics, and Clinical Trial Design. Prior to break out, advocates were polled on subtopics within each major topic area to prioritize them; charts representing results of this polling are presented with each section.
Communications Group

### Communication Issues

| Awareness that not all genetic results have drugable targets (n=14) | 56% |
| Inconsistent language and terms used by healthcare team (n=11) | 44% |
| Use of culturally appropriate and personalized communication (n=9) | 36% |
| Assuring informed treatment decision making (e.g., test results) (n=5) | 20% |
| Genetic assay data: when and why to use? (n=4) | 16% |
| Awareness of alternate treatment plans (n=3) | 12% |
| Community physicians lack awareness of molecular tumor boards (n=2) | 8% |

% of Advocates Agreeing  
N=25 Respondents

Among communication issues considered, the awareness that not all genetic results have drugable targets was identified as the highest priority for discussion, followed by the inconsistent language and terms used by the healthcare team.

### Awareness that not all results will have actionable mutations

Patients in precision medicine clinical trials are not always aware that their cancers may not have actionable mutations.

**SOLUTION(S) DISCUSSED:**
- Informed consent documents should include a checklist or bullet points to bring this information to patients’ attention and trial should include additional educational material in multimedia formats, such as CDs or DVDs. Different formats would also help patients more fully understand the meaning of actionable mutations and why not everyone has one.

### Inconsistent language and terms used by the healthcare team. Definitions in precision medicine vary, as demonstrated by the speakers in this Symposium—even experts do not agree. Additionally, healthcare team members do not all use the same terms to mean the same thing.

**SOLUTION(S) DISCUSSED:**
- Advocates can urge organizations such as the NCI, SWOG, and Alliance to use consistent language, as well as researchers and the medical community.
- Develop glossaries that could be made available in print and other formats, such as CDs and DVDs. Development of a glossary can be done by different organizations and is not solely the responsibility of the trial organizers.
Among logistical issues, access to tumor profiling was the highest priority issue, followed by a 3-way tie between requirement for new biopsy, site resources, and cultural/bureaucratic challenges. A tie-breaking vote identified site resources as the second highest priority topic for consideration.

**Access to tumor profiling**

**SOLUTION(S) DISCUSSED:**
Availability to having tumor profiling needs to be addressed at both the patient and physician levels.
- Patients need education to increase awareness about tumor profiling
- Physicians need education about when tests should be ordered, and how to interpret and apply the information in the reports.

**Site resources**

**Site resources include physical resources, financial resources, and staff skills.**

**SOLUTION(S) DISCUSSED:**
Centers of excellence should be recognized within communities or cancer networks so that patients know where to go for tumor profiling, as well as to obtain information about the process for themselves and their families.
Sites outside the centers of excellence should be identified that can prepare tumor tissue for profiling, and staff should be skilled in handing and storing tumor tissue. Third party vendors should be included to manage tissue handling and storage to promote consistency.
In many cases, patients do not have control over their own tumor tissue once it is removed. This may be problematic if patients later seek to have their tumor tissue profiled to determine whether they might benefit from a certain treatment. However, at the time of tumor removal, patients are not focused on the fate of their excised tumor tissue, but rather on the current treatment and their own recovery. Patients need education regarding the fate of
the removed tumor tissue and need contact information for the surgical center that removed it. Patient consent to use the tissue for research can be an issue and need a better understanding of:

- State laws differ regarding how long tumors are held in pathology laboratories.
- The Common Rule in the Code of Federal Regulations governing human research protections recently changed to allow broad consent for use of tumor tissue. Patients may not understand they can opt out but retain the ability to consent to each individual study that seeks to include their tumor tissue.
- Cooperation between institutions to share samples needs to be promoted.

Financial resources and reimbursement for tumor profiling is a critical consideration. Patients may require preapproval from their insurance company to start a clinical trial treatment and may need reimbursement for out of pocket expenses.

SOLUTION(S) DISCUSSED:
- Private foundations and company access programs may be able to help with this need.
- Education and awareness for the healthcare team of these resources needs to be promoted so that information can be shared with patients.
Among clinical trial design issues, narrow trial eligibility requirements was selected as the highest priority discussion topic, followed by the small size of precision medicine studies and the consequent implications for clinical practice.

**Trial has narrow eligibility requirements and even those with actionable mutations may be denied entry**

Many precision medicine (and other) clinical trials have narrow eligibility requirements, such that patients with the mutation under study, who stand to benefit from the treatment, may not qualify for enrollment.

Any exclusion criteria must be specifically justified, and exclusion criteria must be removed if not clinically or scientifically supported.

**Small size of precision medicine trials precludes influence on clinical practice**

Precision medicine studies can be quite small due to the rarity of individual mutations. This leads to a low number of patients in each mutation group, even though the overall number enrolled in the trial may be quite large.

The low number of patients with each mutation may preclude statistically significant results that would support changes in practice recommendations. In these trials, it is important to analyze differences between responders and nonresponders to potentially identify variables that influence outcomes. Additionally, precision medicine studies in which small groups show strong positive results should be able to influence clinical practice recommendations.
Reconsider endpoints when designing a precision medicine trial. Typical endpoints in cancer studies are progression-free survival and overall survival, but statistical significance in these outcomes can be difficult to achieve with small patient numbers.

Endpoints should be continually evaluated and modified as scientifically and clinically indicated. Even relatively small improvements may add up for patients. For example, if one treatment extends progression-free survival by 10 months, patients may then opt for another treatment that again adds 10 months, and so forth.

Sponsorship

*Research Advocacy Network gratefully acknowledges the support of the following sponsors through competitive grants and agreements.*

Gold Sponsor

Silver Sponsors

*Acknowledgement of other funding:

This symposium was partially funded through a Patient Centered Outcomes Research Institute (PCORI) Eugene Washington PCORI Engagement Award (#6263).*